Latest Breaking News On - Torrey pines investment - Page 1 : comparemela.com

EILEAN THERAPEUTICS RECEIVES CLEARANCE TO INITIATE R/R AML TRIAL WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR

EILEAN THERAPEUTICS RECEIVES CLEARANCE TO INITIATE R/R AML TRIAL WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Amy burdHuman research ethics committeeAi expert systems incEilean therapeuticsPrnewswire eilean therapeuticsChief executive officerTorrey pines investmentExpert systems inc

Expert Systems Expands Partnership with Eilean Therapeutics and Joins Its Best-in-Class PTPN2 Inhibitor Program

/PRNewswire/ Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its.

United statesWestern australiaJohnc byrdBill farleyExpert systems incEilean therapeuticsInhibitor programNess therapeutics incExpert systemsNorth americaTorrey pines investment

EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR

/PRNewswire/ Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule.

Johnc byrdAmy burdExpert systems incPrnewswire eilean therapeuticsEilean therapeutics australia pty ltdHuman research ethics committeeAustralian therapeutics goods administrationEilean therapeuticsEilean therapeutics australia ptyClinical trial notificationIain dukesChief executive officerEilean therapeuticTorrey pines investment

Expert Systems Celebrates Completion of Single Dose Studies and Start of Multiple Human Dosing for Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor, Achieved in Just 3 Years

Expert Systems Celebrates Completion of Single Dose Studies and Start of Multiple Human Dosing for Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor, Achieved in Just 3 Years
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesWestern australiaJohnc byrdBill farleyEilean therapeuticsExpert systems incSystems celebrates completionSingle dose studiesMultiple human dosingTorrey pines investmentExpert systemExpert systemsNorth america

Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years

/PRNewswire/ Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant achievement in collaboration with Eilean Therapeutics.

Western australiaUnited statesBill farleyJohnc byrdExpert systems incEilean therapeuticsHuman research ethics committeeTorrey pines investmentExpert systemExpert systemsNorth americaHealth care amp hospitalsMedical pharmaceuticalsBanking amp financial servicesComputer amp electronicsArtificial intelligence